No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HRTX240816P3000
- 0.18
- +0.03+20.00%
15min DelayClose Jul 22 16:00 ET
0.18High0.18Low
0.18Open0.15Pre Close1 Volume790 Open Interest3.00Strike Price18.00Turnover115.08%IV11.88%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type-0.3536Delta0.3861Gamma11.64Leverage Ratio-0.0070Theta-0.0009Rho-4.12Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.Zynrelef will be included under Medicare's Outpatient
Express News | Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And...
Express News | Heron Therapeutics Announces the Inclusion of Zynrelef® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the Opps and the Asc Payment System
Breakeven On The Horizon For Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Heron Therapeutics, Inc., a commercial-stage
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics Down Over 19%, On Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Heron Therapeutics Inc.(HRTX) is currently at $2.79, down $0.68 or 19.62% --Would be lowest close since May 10, 2024, when it closed at $2.77 --On pace for largest percent decrease since May 12, 202
Comments
$Heron Therapeutics(HRTX.US$ Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
MT Newswires· 2 mins ago
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.
Zynrelef will be included under Medicare's Outpatient Prospective Payment System and the Medicare Ambulatory Surgical Center, beginning April 1.
The company said Zynrelef was qualified because it is appro...
MT Newswires· 2 mins ago
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.
Zynrelef will be included under Medicare's Outpatient Prospective Payment System and the Medicare Ambulatory Surgical Center, beginning April 1.
The company said Zynrelef was qualified because it is appro...
$Heron Therapeutics(HRTX.US$ Heron Therapeutics Inc - U.S. Food and Drug Administration ("FDA") Assigned a Prescription Drug User Fee Act ("Pdufa") Goal Date of September 23, 2024
$Heron Therapeutics(HRTX.US$ Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for Zynrelef® Vial Access Needle ("Van")
1
1
$Heron Therapeutics(HRTX.US$
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...
1
Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
1
Read more